The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

Corcept Therapeutics Inc (CORT) reports increased revenue and expanding market opportunities, despite facing operational hurdles and ongoing litigation.

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 Corcept Therapeutics Incorporated (NASDAQ: CORT), a ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept sees 40% growth in 2025 revenue with promising trials, expanded patient base, and strong projections. Read my ...

A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a ...

Corcept Therapeutics (NASDAQ: CORT) reported first quarter earnings that beat analyst expectations, but revenue fell short of estimates, sending shares down 8.7% ...

Corcept is studying relacorilant in a variety of serious disorders in addition to ovarian cancer, including endogenous hypercortisolism (Cushing’s syndrome) and prostate cancer. Relacorilant is ...

Corcept Therapeutics Incorporated (NASDAQ ... plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.